Wockhardt receives US FDA nod for pain killer oxycodone

The Mumbai-based Wockhardt has received final approval from the US Food & Drug Administration (US FDA) for marketing 5mg/ 5ml of oxycodone HCl liquid, which is used in treatment of moderate to severe acute and chronic pain. According to IMS Health, the total market for this product in the US is about $58 million. Oxycodone is used extensively in management of pain, especially in opioid tolerant patients. Wockhardt already markets several other controlled substance products in the US and generally has a leading presence in the liquid formulations segment.
 
“We are delighted to receive this ANDA approval for our oxycodone liquid. We have filed several ANDA’s over the last couple of years from our Morton Grove Pharmaceuticals facility in Illinois, USA, especially for liquid products. This is only the first of few others we expect soon,” said Dr Habil Khorakiwala, founder chairman & group CEO, Wockhardt.
 
Wockhardt will be manufacturing the oxycodone HCl liquid at its facility in Morton Grove, Illinois.